While cost-effective high-throughput technologies provide an increasing amount of data, the
analyses of single layers of data seldom provide causal relations. Multi-omics data …

Background Genetic alterations of somatic cells can drive non-malignant clone formation
and promote cancer initiation. However, the link between these processes remains unclear …

Identifying molecular cancer drivers is critical for precision oncology. Multiple advanced
algorithms to identify drivers now exist, but systematic attempts to combine and optimize …

Summary The Cancer Genome Atlas (TCGA) has catalyzed systematic characterization of
diverse genomic alterations underlying human cancers. At this historic junction marking the …

High‐grade serous ovarian cancer (HGSC) is characterized by poor outcome, often
attributed to the emergence of treatment‐resistant subclones. We sought to measure the …

Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous cancer composed of
at least 2 molecular subtypes that differ in gene expression and distribution of mutations …

Large-scale cancer genomic studies have revealed that the genetic heterogeneity of the
same type of cancer is greater than previously thought. A key question in cancer genomics is …

The prevalence of neutral mutations in cancer cell population impedes the distinguishing of
cancer-causing driver mutations from passenger mutations. To systematically prioritize the …

Motivation Several molecular events are known to be cancer-related, including genomic
aberrations, hypermethylation of gene promoter regions and differential expression of …

Cancer is driven by distinctive sorts of changes and basic variations in genes. Recognizing
cancer driver genes is basic for accurate oncological analysis. Numerous methodologies to …